Related Experiment Video

Updated: Jul 14, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004

Ulrik M Overgaard1, Jannik Helweg-Larsen

  • 1Department of Internal Medicine, Nykøbing Falster Sygehus, Rigshospitalet, Copenhagen, Denmark.

Scandinavian Journal of Infectious Diseases
|June 20, 2007
PubMed

Insights

Pneumocystis pneumonia (PCP) in HIV-negative patients is often linked to steroid use and lymphopenia. Early diagnosis and treatment are crucial for survival, as low CD4 counts alone are insufficient for risk assessment.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pulmonology

Background:

  • Pneumocystis jiroveci pneumonia (PCP) is an opportunistic infection primarily affecting immunocompromised individuals.
  • While commonly associated with HIV/AIDS, PCP also occurs in HIV-negative patients with various underlying conditions.
  • Identifying risk factors for PCP in HIV-negative populations is essential for timely diagnosis and management.

Purpose of the Study:

  • To investigate the risk factors associated with Pneumocystis jiroveci pneumonia (PCP) in HIV-negative patients.
  • To describe the predisposing conditions, treatment-related factors, and clinical characteristics of PCP in this patient group.
  • To evaluate the utility of CD4 counts and lymphopenia in identifying patients at risk for PCP.

Main Methods:

  • A retrospective study was conducted at Rigshospitalet University Hospital from 2002 to 2004.
  • Fifty cases of PCP were identified based on histology, PCR, and clinical symptoms.
  • Data on predisposing conditions, treatments, prophylaxis, and laboratory findings were analyzed.

Main Results:

  • The most common predisposing conditions were hematological malignancy (72%) and inflammatory diseases (14%).
  • Steroid usage (76%) and chemotherapy (72%) were the most frequent treatment-related risk factors.
  • Lymphopenia was present in 78% of patients at diagnosis; low CD4 counts (<300 cells/µL) were observed in only 52% of those tested.
  • Overall mortality was 14%, significantly associated with delayed diagnosis and treatment.

Conclusions:

  • PCP should be suspected in immunocompromised, HIV-negative patients, particularly those on steroid treatment or presenting with lymphopenia.
  • While low CD4 counts can indicate risk, they are insufficient for guiding PCP risk identification or prophylaxis in HIV-negative individuals.
  • Prophylaxis was rarely used, highlighting a potential gap in preventive strategies for at-risk HIV-negative patients.

More Related Videos

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...